<?xml version="1.0" encoding="UTF-8"?>
<p>A DNA vaccine under clinical development is developed by US Naval Medical Research Center, and it contains prM and E genes. Monovalent DENV-1 prM and E DNA (D1ME) vaccines showed immunogenicity in Phase I clinical trial after being demonstrated conferring protection in a monkey model (
 <xref rid="B10" ref-type="bibr">Beckett et al., 2011</xref>). The neutralizing antibody was detectable only in the vaccine group receiving higher dose of DNA, and its titer was low. Therefore, tetravalent formulations of this vaccine were tested with combination of Vaxfectin
 <sup>Â®</sup> adjuvant to improve its immunogenicity in further clinical trials (
 <xref rid="B141" ref-type="bibr">Porter et al., 2012</xref>), much of its results have not been published.
</p>
